Prostate, 20230239 “XALience”

ClinicalTrials.gov ID:  NCT07213674

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Cancer Q&A with HOA: March is Multiple Myeloma Awareness Month

Cancer Q&A with HOA
March is Multiple Myeloma Awareness Month

Cancer Q&A with HOA: March is Multiple Myeloma Awareness Month

Clarity Through Second Opinions

Cancer Q&A with HOA
Receiving Clarity Through Second Opinions

Cancer Q&A with HOA: Receiving Clarity Through Second Opinions

Urothelial, S1937

ClinicalTrials.gov ID: NCT04579224

Prostate, Viper, URCC 22053

ClinicalTrials.gov ID: NCT05838716

Lung, Merck V940 INTerpath-009

ClinicalTrials.gov ID: NCT06623422

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy.

Lung, D702GC0000, Artemide-Lung04

ClinicalTrials.gov ID NCT06868277

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer.

Lung, D763QC00001, Tropion-Lung17

ClinicalTrials.gov ID: NCT07291037

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations 

Pages